Seeding Technology Ventures
We invest in researchers, technologies and businesses that will
change the world for the better.
Co-investment & Grants
We invest in innovative technologies.
We are a unique commercialisation fund helping researchers from our partner research organisations turn their ideas into products and services. We support innovations that solve market problems and create a positive impact for our community. Uniseed invests over a broad range of technology sectors and has exited ten investments, to date.
How we help
Seed capital investment
We invest in your innovation to help you progress and de-risk from both a technical and commercial perspective.
We believe in supporting your progress through collaboration and mentoring.
You will have the ability to access Uniseed’s network of industry experts, co-investors and start-up experts.
We help you build your strategy, manage your intellectual property and identify commercial partners.
Rewards & recognition
Boost career profile, publications, conferences, patent publications and increase your visibility.
Make an impact
Impact our community by solving market problems through your innovation.
Our Process ›
Step 1: Make Contact
Get in contact through your commercialisation office or directly with us. Initial meetings and discussions will start with an Investment Manager. Tell us about your innovative opportunity and we will assist in identifying the most appropriate pathway forward.
Step 2: Pitch to Us
Promising eligible opportunities will have the opportunity to pitch to the Uniseed Investment Committees (which convenes monthly) and receive feedback.
Step 3: Due Diligence & Negotiation
Uniseed conducts detailed due diligence on your opportunity which may include further presentation(s) to our investment committee. We syndicate promising deals with your co-investors (as required)
Step 4: Investment & Growth
Investment capital is provided. Uniseed provides expert guidance and access to networks. We also help to develop, grow and scale your innovation.
Step 5: Impact & Exit
Generate impact through your innovation. Receive awards and recognition. Exit and achieve a return for shareholders.
ENA Respiratory Selected for the BLUE KNIGHT™ Program to Accelerate Development of Pan-Antiviral Nasal Spray
Sydney, Australia, 12th May 2022 - ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and...
UniSuper, the $106 billion fund now open to all Australians, has today announced it has secured an investment relationship with Australia’s longest-established early-stage commercialisation fund manager - Uniseed 24 March 2022 - Uniseed, like UniSuper,...
-- ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections Sydney, Australia, 16 March 2022 – Uniseed...